Monopar Therapeutics (MNPR, Financial) will join the Russell 3000 Index, reflecting a broader market presence, along with an entry into the Russell 2000 Index, which focuses on small-cap companies. This change is scheduled after U.S. stock markets close on June 27, 2025. The inclusion results from the annual reconstitution of the Russell U.S. Indexes, initially announced on May 23, 2025, and updated on May 30, 2025. This development marks a significant step for Monopar Therapeutics as it gains exposure to a wider investor base.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Monopar Therapeutics Inc (MNPR, Financial) is $58.00 with a high estimate of $76.00 and a low estimate of $40.00. The average target implies an upside of 93.27% from the current price of $30.01. More detailed estimate data can be found on the Monopar Therapeutics Inc (MNPR) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Monopar Therapeutics Inc's (MNPR, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
